Upstream Biosciences Inc.' Potential Tropical Disease Treatments Demonstrate Promising Signs of Efficacy at McGill University

VANCOUVER, BC--(Marketwire - October 07, 2008) - Upstream Biosciences Inc. (OTCBB: UPBS) today announced that its second generation of novel antiparasitic agents demonstrated in vitro efficacy against both Leishmaniasis and Trypanosomiasis. Upstream's novel compounds were tested by Dr. Armando Jardim at the Institute of Parasitology of McGill University in Montreal, Quebec, Canada. Upstream continues to collaborate with McGill to perform further testing on its potential tropical disease treatments. The Institute of Parasitology is recognized internationally for its research on infectious parasitic diseases.

Back to news